{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-2.3","upperLimit":"10.1","value":"-0.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"151"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-2.3","upperLimit":"9.5","value":"-0.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"160"}],"units":"Participants"}],"title":"Week 18"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-2.3","upperLimit":"10.8","value":"-0.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"139"}],"units":"Participants"}],"title":"Week 42"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-2.3","upperLimit":"9.1","value":"0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"104"}],"units":"Participants"}],"title":"Week 66"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-2.3","upperLimit":"9.0","value":"-0.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"82"}],"units":"Participants"}],"title":"Week 90"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"265"}],"units":"Participants"}],"description":"The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \\<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range","dispersionType":"Full Range","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"},{"description":"Participants who were treated with everolimus either in the Core or Extension phases of the study and were evaluated for longer term safety and efficacy.","id":"OG003","title":"Everolimus Long Term Evaluation (LTE)"}],"paramType":"MEDIAN","populationDescription":"The Long Term Evaluation (LTE) efficacy set consists of all patients who received at least one dose of everolimus and had at least one efficacy assessment while on everolimus.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 18, 42, 66 and 90","title":"Long Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}